
Monoamine Oxidase Inhibitors - Pipeline Insight, 2025
Description
DelveInsight’s, “Monoamine Oxidase Inhibitor (MAOIs) - Pipeline Insight, 2025” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Monoamine Oxidase Inhibitor (MAOIs) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Monoamine Oxidase Inhibitor (MAOIs): Overview
Monoamine oxidase (MAO; EC 1.4.3.4.) is a widely distributed mitochondrial enzyme with high expression levels in gastro-intestinal and hepatic as well as neuronal tissues. There are two types of monoamine oxidase, A and B. The MOA A is mostly distributed in the placenta, gut, and liver, but MOA B is present in the brain, liver, and platelets.
Function - The enzyme catalyzes the oxidative deamination of a variety of monoamines, both endogenous and exogenous, and has major roles in metabolizing released neurotransmitters, and in detoxification of a large variety of endogenous and exogenous amines.
Monoamine Oxidase Inhibitor (MAOIs) - Monoamine Oxidase Inhibitor (MAOIs) are responsible for blocking the monoamine oxidase enzyme. The monoamine oxidase enzyme breaks down different types of neurotransmitters from the brain: norepinephrine, serotonin, dopamine, and tyramine. MAOIs inhibit the breakdown of these neurotransmitters thus, increasing their levels and allowing them to continue to influence the cells that have been affected by depression.
Monoamine Oxidase Inhibitor (MAOIs) Emerging Drugs Chapters
This segment of the Monoamine Oxidase Inhibitor (MAOIs) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Monoamine Oxidase Inhibitor (MAOIs) Emerging Drugs
Further product details are provided in the report……..
Monoamine Oxidase Inhibitor (MAOIs): Therapeutic Assessment
This segment of the report provides insights about the different Monoamine Oxidase Inhibitor (MAOIs) drugs segregated based on following parameters that define the scope of the report, such as:
Monoamine Oxidase Inhibitor (MAOIs): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Monoamine Oxidase Inhibitor (MAOIs) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Monoamine Oxidase Inhibitor (MAOIs) drugs.
Report Highlights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Monoamine Oxidase Inhibitor (MAOIs): Overview
Monoamine oxidase (MAO; EC 1.4.3.4.) is a widely distributed mitochondrial enzyme with high expression levels in gastro-intestinal and hepatic as well as neuronal tissues. There are two types of monoamine oxidase, A and B. The MOA A is mostly distributed in the placenta, gut, and liver, but MOA B is present in the brain, liver, and platelets.
Function - The enzyme catalyzes the oxidative deamination of a variety of monoamines, both endogenous and exogenous, and has major roles in metabolizing released neurotransmitters, and in detoxification of a large variety of endogenous and exogenous amines.
Monoamine Oxidase Inhibitor (MAOIs) - Monoamine Oxidase Inhibitor (MAOIs) are responsible for blocking the monoamine oxidase enzyme. The monoamine oxidase enzyme breaks down different types of neurotransmitters from the brain: norepinephrine, serotonin, dopamine, and tyramine. MAOIs inhibit the breakdown of these neurotransmitters thus, increasing their levels and allowing them to continue to influence the cells that have been affected by depression.
Monoamine Oxidase Inhibitor (MAOIs) Emerging Drugs Chapters
This segment of the Monoamine Oxidase Inhibitor (MAOIs) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Monoamine Oxidase Inhibitor (MAOIs) Emerging Drugs
- Ladostigil: Avraham Pharmaceuticals
- Safinamide: Newron Pharmaceuticals
Further product details are provided in the report……..
Monoamine Oxidase Inhibitor (MAOIs): Therapeutic Assessment
This segment of the report provides insights about the different Monoamine Oxidase Inhibitor (MAOIs) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Monoamine Oxidase Inhibitor (MAOIs)
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Monoamine Oxidase Inhibitor (MAOIs): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Monoamine Oxidase Inhibitor (MAOIs) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Monoamine Oxidase Inhibitor (MAOIs) drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Monoamine Oxidase Inhibitor (MAOIs) R&D. The therapies under development are focused on novel approaches for Monoamine Oxidase Inhibitor (MAOIs).
- Monoamine Oxidase Inhibitor (MAOIs) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Monoamine Oxidase Inhibitor (MAOIs) drugs?
- How many Monoamine Oxidase Inhibitor (MAOIs) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Monoamine Oxidase Inhibitor (MAOIs)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Monoamine Oxidase Inhibitor (MAOIs) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Monoamine Oxidase Inhibitor (MAOIs) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Avraham Pharmaceuticals
- PREXA SANTE
- Newron Pharmaceuticals
- Oryzon Genomics
- Ipsen
- Provepharm
- Roche
- Changzhou Si Yao Pharmaceutical
- Ladostigil
- Methylthioninium chloride
- Safinamide
- Vafidemstat
- BN 82451
- ProvayBlue
- Sembragiline
- Rasagiline
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Monoamine Oxidase Inhibitor (MAOIs): Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Monoamine Oxidase Inhibitor (MAOIs) – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Monoamine Oxidase Inhibitor (MAOIs) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Monoamine Oxidase Inhibitor (MAOIs) Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Pre-registration)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Safinamide: Newron Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Rasagiline: Changzhou Si Yao Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Monoamine Oxidase Inhibitor (MAOIs) Key Companies
- Monoamine Oxidase Inhibitor (MAOIs) Key Products
- Monoamine Oxidase Inhibitor (MAOIs)- Unmet Needs
- Monoamine Oxidase Inhibitor (MAOIs)- Market Drivers and Barriers
- Monoamine Oxidase Inhibitor (MAOIs)- Future Perspectives and Conclusion
- Monoamine Oxidase Inhibitor (MAOIs) Analyst Views
- Monoamine Oxidase Inhibitor (MAOIs) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.